Document:

Exhibit 10.30

 

DATED 5 APRIL 2012

 

Amsterdam Molecular Therapeutics (AMT) B.V.

 

and

 

Amsterdam Molecular Therapeutics (AMT) IP B.V.

 

as the Transferees

 

and

 

Amsterdam Molecular Therapeutics (AMT) Holding N.V.

 

as the Transferor

 

 

DEED OF ASSIGNMENT OF
 CERTAIN ASSETS AND
 LIABILITIES OF AMSTERDAM
 MOLECULAR THERAPEUTICS
 (AMT) HOLDING N.V.

 

 

 

 

TABLE OF CONTENTS

 

	
Clause
    	
 
    	
Headings
    	
 
    	
Page
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
1.
    	
 
    	
INTERPRETATION
    	
 
    	
2
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
2.
    	
 
    	
TRANSFER OF OWNERSHIP
    	
 
    	
2
    
	
 
    	
 
    	
2.1.
    	
Agreement to transfer
    	
 
    	
2
    
	
 
    	
 
    	
2.2.
    	
Business Goodwill and Know How
    	
 
    	
2
    
	
 
    	
 
    	
2.3.
    	
Business Intellectual Property Rights
    	
 
    	
2
    
	
 
    	
 
    	
2.4.
    	
Business Assets
    	
 
    	
3
    
	
 
    	
 
    	
2.5.
    	
Business Liabilities
    	
 
    	
3
    
	
 
    	
 
    	
2.6.
    	
Contracts and Business Permits
    	
 
    	
3
    
	
 
    	
 
    	
2.7.
    	
Other assets and liabilities
    	
 
    	
3
    
	
 
    	
 
    	
2.8.
    	
Excluded assets and liabilities
    	
 
    	
3
    
	
 
    	
 
    	
2.9.
    	
Other transfer requirements
    	
 
    	
4
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
3.
    	
 
    	
TRANSFER OF SELLER LOANS
    	
 
    	
4
    
	
 
    	
 
    	
3.1.
    	
Agreement to transfer
    	
 
    	
4
    
	
 
    	
 
    	
3.2.
    	
VAT
    	
 
    	
4
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4.
    	
 
    	
ECONOMIC OWNERSHIP TRANSFER AGREEMENT
    	
 
    	
5
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
5.
    	
 
    	
GOVERNING LAW AND JURISDICTION
    	
 
    	
5
    
	
 
    	
 
    	
5.1.
    	
Governing law
    	
 
    	
5
    
	
 
    	
 
    	
5.2.
    	
Jurisdiction
    	
 
    	
5
    

 

 

THIS DEED is made on 5 April 2012.

 

BETWEEN:

 

(1)                                Amsterdam Molecular Therapeutics (AMT) B.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34275365;

 

(2)                                Amsterdam Molecular Therapeutics (AMT) IP B.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34275369;

 

(Amsterdam Molecular Therapeutics (AMT) B.V. and Amsterdam Molecular Therapeutics (AMT) IP B.V. collectively also the “Transferees” and each individually a “Transferee”), and

 

(3)                                Amsterdam Molecular Therapeutics (AMT) Holding N.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 33301321 (the “Transferor”)

 

The parties to this Agreement are hereinafter collectively referred to as the “Parties” and individually as a “Party”.

 

RECITALS:

 

(1)                                Pursuant to an agreement dated 16 February 2012 (the “Economic Ownership Transfer Agreement”) the Transferor contributed the economic ownership (economische eigendom) of the Business (as defined in the Economic Ownership Transfer Agreement) to the Transferees subject to and upon the terms and conditions of the Economic Ownership Transfer Agreement.

 

(2)                                The Transferor and the Transferees wish to transfer the legal title (juridische eigendom) to the Business to the Transferees as contemplated in the Economic Ownership Transfer Agreement by entering into this asset transfer agreement (the “Deed of Assignment”) and performing all other actions necessary to transfer the legal title to, and therefore the ownership of, the Business to the Transferees in accordance with Clause 2 of the Economic Ownership Transfer Agreement.

 

(3)                                The conditions stipulated in Clause 3 of the Economic Ownership Transfer Agreement have been fulfilled or waived and parties have agreed that the legal titel of the Business shall be transferred on the execution of this Deed of Assignment, but prior to the Completion Date.

 

(4)                                Furthermore, the Transferor and the Transferees wish to transfer the legal title (juridische eigendom) and the economic ownership (economische eigendom) of the Seller Loans to the Transferees and to effectuate such transfer by entering into this Deed of Assignment and performing all other actions necessary to effectuate such transfer.

 

(5)                                The Transferor has obtained all internal corporate approvals required for the execution and performance of this Deed of Assignment.

 

1

 

IT IS AGREED as follows:

 

1.                                     INTERPRETATION

 

Definitions used in this Deed of Assignment have the same meaning as given to them in the Economic Ownership Transfer Agreement unless stated otherwise, and the provisions of Clause 1 (Interpretation) of the Economic Ownership Transfer Agreement shall apply to this Agreement.

 

2.                                     TRANSFER OF OWNERSHIP

 

2.1.                           Agreement to transfer

 

2.1.1.                           Subject to the terms and conditions of this Deed of Assignment and the Economic Ownership Transfer Agreement, the Transferor hereby transfers and delivers the legal title to the Business to the Transferees and the Transferees hereby accept and assume from the Transferor the Business, including the Business Assets and the Business Liabilities, whereby:

 

(A)                              the legal title to the Business Intellectual Property Rights is transferred to AMT IP BV; and

 

(B)                              the legal title to the other Business Assets and Business Liabilities is transferred to AMT BV.

 

2.1.2.                           The Transferees and the Transferor acknowledge that to the extent the transfer and delivery of any of the Business Assets and/or Business Liabilities requires a deed (akte) this Deed of Assignment constitutes a deed of transfer for such Business Assets and Business Liabilities to take effect from the execution of this Deed of Assignment.

 

2.1.3.                           The transfer and delivery of the Business Assets and Business Liabilities shall further be effectuated as set out in Clause 2 of the Economic Ownership Transfer Agreement.

 

2.1.4.                           The legal title to the respective parts of the Business shall be transferred to AMT IP BV and AMT BV by way of a contribution in kind (inbreng in natura) on the ordinary shares in the capital of the Transferees held by the Transferor, without the issuance of new shares. The value of such contribution will be recorded as share premium (agiostorting) in the books of AMT IP BV and AMT BV.

 

2.2.                           Business Goodwill and Know How

 

The Business Goodwill and Know How are hereby transferred to the Transferees.

 

2.3.                           Business Intellectual Property Rights

 

The Business Intellectual Property Rights are hereby transferred to AMT IP BV. AMT IP BV shall register the registered Business Intellectual Property Rights in its name in all relevant registers. To the extent any of the Business Intellectual Property Rights consists of a license (“Business Permit”), such license shall, if permitted under the license, be transferred in accordance with the relevant requirements of such license and in accordance with Clause 2.6, simultaneously with the execution of this Deed of Assignment.

 

2

 

2.4.                           Business Assets

 

2.4.1.                           All Business Assets, including but not limited to ICT, inventory and equipment, business records, business stock and work in progress and all other Business Assets that are transferable by delivery (bezitsverschaffing), to the extent such Business Assets are not held by others for or on behalf of the Transferor, are hereby transferred and delivered to the relevant Transferee by giving access to the places where these Business Assets are physically located and by having delivered to the relevant Transferee all keys and title documents and other evidence of ownership.

 

2.4.2.                           To the extent that any of the Business Assets that are mentioned in Clause 2.4.1 are held by others for or on behalf of the Transferor, such Business Assets are transferred and delivered to the relevant Transferee by a notice from the Transferor to the other parties, also on behalf of the relevant Transferee, instructing such party to hold such Business Assets for or on behalf of the relevant Transferee to take effect prior to the Completion Date. The Transferor shall send the relevant Transferee a copy of such notices.

 

2.4.3.                           To the extent any of the Business Assets consists of a license, such license shall, if permitted under the license, be transferred in accordance with the relevant requirements of such license and in accordance with Clause 2.6 simultaneously with the execution of this Deed of Assignment.

 

2.5.                           Business Liabilities

 

The Business Liabilities are hereby transferred to the relevant Transferee in accordance with the terms and conditions of the Economic Ownership Transfer Agreement.

 

2.6.                           Contracts and Business Permits

 

All Contracts and Business Permits are hereby transferred to the relevant Transferee in accordance with the relevant requirements of such Contract or Business Permit and the terms and conditions of the Economic Ownership Transfer Agreement.

 

2.7.                           Other assets and liabilities

 

Notwithstanding the provisions of Clause 2.1 up to and including 2.6, the Transferor hereby transfers and delivers the legal title of all other existing assets, business assets, liabilities and/or contracts of the Transferor, if any, to AMT BV and AMT BV hereby acquire and accept from the Transferor all such other assets, including but not limited to cash, business assets, liabilities and/or contracts.

 

2.8.                           Excluded assets and liabilities

 

The provisions of this Deed of Assignment do not extend to the Loan Notes, Convertible Loan Note Agreement, Sale Shares, Administration, rights and obligations pursuant to the BAA, the listing agreement between the Transferor and Euronext Amsterdam, the contract with the ENL agent and the payment agent, the liquidity provider agreement between the Transferor and Kempen & Co N.V., the D&O Insurance policy of the Transferor, any outstanding obligations under any stock option plan or other employee plan of the Transferor and any and all agreements the Transferor entered into with Senter Novem. This

 

3

 

Deed of Assignment does therefore not constitute a transfer of the legal title to any of the assets and contracts mentioned in this Clause 2.8.

 

2.9.                           Other transfer requirements

 

If and insofar the transfer of any existing Business Assets or Business Liabilities requires any other acts for the transfer of the legal title to such Business Assets or Business Liabilities than mentioned in this Deed of Assignment, Parties shall satisfy such requirements and comply with the relevant statutory provisions, as soon as reasonably and practically possible.

 

3.                                     TRANSFER OF SELLER LOANS

 

3.1.                           Agreement to transfer

 

3.1.1.                           Subject to the terms and conditions of this Deed of Assignment the Transferor hereby contributes to

 

(A)                              AMT BV and AMT BV hereby accept from the Transferor, the legal title and economic ownership of the AMT BV Seller Loan; and

 

(B)                              AMT IP BV and AMT IP BV hereby accept from the Transferor, the legal title and economic ownership of the AMT IP BV Seller Loan.

 

3.1.2.                           The AMT BV Seller Loan and the AMT IP BV Seller Loan are with the effect as of the signing date of this Deed of Assignment transferred to AMT BV and AMT IP BV, respectively, by way of a contribution in kind (inbreng in natura) on the ordinary shares in the capital of AMT BV and AMT IP BV held by the Transferor, without the issuance of new shares. The value of the AMT BV Seller Loan and the AMT IP BV Seller Loan will be recorded as share premium (agiostorting) in the books of AMT BV and AMT IP BV.

 

3.1.3.                           As a result of the contribution set forth in Clause 3.1 above:

 

(A)                              AMT BV is both the debtor and the creditor under the AMT BV Seller Loan; and

 

(B)                              AMT IP BV is both the debtor and the creditor under the AMT IP BV Seller Loan,

 

resulting in the cancellation of the AMT BV Seller Loan and the AMT IP BV Seller Loan.

 

3.2.                           VAT

 

The Transferor and the Transferees are included in a fiscal unity for Dutch VAT purposes within the meaning of article 7 paragraph 4 Dutch VAT Act 1968 (Wet op de omzetbelasting 1968) and the Transferor and the Transferees expressly agree that the transfer of the legal title and economic ownership of the Seller Loans occurs within the fiscal unity for Dutch VAT and that therefore no VAT should become due as a result of such transfer.

 

4

 

4.                                     ECONOMIC OWNERSHIP TRANSFER AGREEMENT

 

The Economic Ownership Transfer Agreement constitutes an integral part of this Deed of Assignment and is hereby incorporated into this Deed of Assignment by this reference. This Deed of Assignment shall in no way impair or affect the Economic Ownership Transfer Agreement that shall remain in full force and effect despite Completion.

 

5.                                     GOVERNING LAW AND JURISDICTION

 

5.1.                           Governing law

 

This Deed of Assignment is governed by the laws of the Netherlands, but excluding the Vienna Convention for the International Sale of Goods.

 

5.2.                           Jurisdiction

 

The competent court in Amsterdam, the Netherlands, shall have exclusive jurisdiction to settle any dispute in connection with this Deed of Assignment without prejudice to the right of appeal and that of appeal to the Supreme Court.

 

5

 

THUS AGREED AND SIGNED ON 5 APRIL 2012,

 

 

	
Amsterdam   Molecular Therapeutics (AMT) B.V.
    	
 
    	
Amsterdam   Molecular Therapeutics (AMT) IP B.V.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: /s/Joern   Aldag
    	
 
    	
By: /s/Joern   Aldag
    
	
 
    	
 
    	
 
    
	
Title: CEO
    	
 
    	
Title: CEO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Amsterdam   Molecular Therapeutics (AMT) Holding N.V.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: /s/Joern   Aldag
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Title: CEO
    	
 
    	
 
    

 

6EXHIBIT 10.31

 

DATED 16 February 2012

 

Amsterdam Molecular Therapeutics (AMT) B.V.

 

and

 

Amsterdam Molecular Therapeutics (AMT) IP B.V.

 

as the Purchasers

 

Amsterdam Molecular Therapeutics (AMT) Holding N.V.

 

as the Seller

 

 

AGREEMENT FOR TRANSFER
 OF CERTAIN ASSETS AND
 LIABILITIES OF AMSTERDAM
 MOLECULAR THERAPEUTICS
 (AMT) HOLDING N.V.

 

 

 

 

TABLE OF CONTENTS

 

	
Clause
    	
 
    	
Headings
    	
 
    	
Page
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
1.
    	
 
    	
INTERPRETATION
    	
 
    	
1
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
2.
    	
 
    	
TRANSFER
    	
 
    	
2
    
	
 
    	
 
    	
2.1.
    	
Sale of the Business
    	
 
    	
2
    
	
 
    	
 
    	
2.2.
    	
Sale of the Seller Loans
    	
 
    	
3
    
	
 
    	
 
    	
2.3.
    	
VAT
    	
 
    	
3
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
3.
    	
 
    	
TRANSFER OF LEGAL TITLE
    	
 
    	
3
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
4.
    	
 
    	
CONFIDENTIALITY AND ANNOUNCEMENTS
    	
 
    	
3
    
	
 
    	
 
    	
4.1.
    	
Confidentiality
    	
 
    	
3
    
	
 
    	
 
    	
4.2.
    	
Announcements
    	
 
    	
4
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5.
    	
 
    	
GENERAL PROVISIONS
    	
 
    	
4
    
	
 
    	
 
    	
5.1.
    	
Notices
    	
 
    	
4
    
	
 
    	
 
    	
5.2.
    	
Entire agreement
    	
 
    	
4
    
	
 
    	
 
    	
5.3.
    	
Amendment
    	
 
    	
5
    
	
 
    	
 
    	
5.4.
    	
Assignment
    	
 
    	
5
    
	
 
    	
 
    	
5.5.
    	
Partial invalidity
    	
 
    	
5
    
	
 
    	
 
    	
5.6.
    	
Rescission after Completion
    	
 
    	
5
    
	
 
    	
 
    	
5.7.
    	
Governing law
    	
 
    	
5
    
	
 
    	
 
    	
5.8.
    	
Jurisdiction
    	
 
    	
5
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
SCHEDULE 1 (DEFINITIONS)
    	
 
    
	
 
    	
 
    
	
SCHEDULE 2 (BUSINESS   INTELLECTUAL PROPERTY RIGHTS & FURTHER ASSETS AND LIABILITIES)
    	
 
    

 

i

 

Economic Ownership Transfer Agreement

 

THIS AGREEMENT is made on 16 February 2012

 

BETWEEN:

 

Amsterdam Molecular Therapeutics (AMT) B.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34275365;

 

Amsterdam Molecular Therapeutics (AMT) IP B.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34275369;

 

(Amsterdam Molecular Therapeutics (AMT) B.V. and Amsterdam Molecular Therapeutics (AMT) B.V IP B.V. collectively also the “Purchasers” and each individually a “Purchaser”) and

 

Amsterdam Molecular Therapeutics (AMT) Holding N.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 3330132 (the “Seller”)

 

The parties to this Agreement are hereinafter collectively referred to as the “Parties” and individually as a “Party”.

 

RECITALS:

 

(1)                                The Seller is involved in the business of the development of human gene based therapies. In connection therewith, the Seller acts as the holding company for the Purchasers and is listed on NYSE Euronext in Amsterdam.

 

(2)                                The Seller and the Purchasers have reached an agreement with respect to the sale and acquisition, as a going concern, of the economic ownership (economische eigendom) of the Business (as defined herein), subject to and upon the terms and conditions of this Agreement.

 

(3)                                In connection with the transfer of the economic ownership of the Business, the Seller and the Purchasers have agreed to the transfer by the Seller to the Purchasers of the Seller Loans after signing of the BAA, but prior to the Completion Date unless such transfer has materially adverse consequences for the Seller or the Purchasers.

 

(4)                                The Seller has obtained all internal corporate approvals required for the execution and performance of this Agreement.

 

IT IS AGREED as follows:

 

1.                                     INTERPRETATION

 

1.1.                           In this Agreement the definitions in Schedule 1 (Definitions) are used.

 

1.2.                           In this Agreement, unless otherwise specified:

 

1.2.1.                           the masculine gender shall include the feminine and the neuter and vice versa;

 

1.2.2.                           references to a person shall include a reference to any individual, company, association, partnership or joint venture;

 

 

1.2.3.                           references to “include” and “including” shall be treated as references to “include without limitation” or “including without limitation”;

 

1.2.4.                           references to documents in “agreed form” shall be to documents agreed between the Parties, annexed to this Agreement and initialled for identification by the Parties;

 

1.2.5.                           unless the context requires otherwise, words in the singular shall include the plural and vice versa;

 

1.2.6.                           the headings are for identification only and shall not affect the interpretation of this Agreement.

 

2.                                     TRANSFER

 

2.1.                           Sale of the Business

 

2.1.1.                           Subject to the terms and conditions of this Agreement the Seller hereby contributes to the Purchasers and the Purchasers hereby accept or assume (as the case may be), as a going concern, from the Seller, the economic ownership of the Business with the effect as of the signing date of this Agreement (the Effective Date), whereby:

 

(A)                              the economic ownership of the Business Intellectual Property Rights is hereby transferred to AMT IP BV; and

 

(B)                              the economic ownership of the other Business Assets and Business Liabilities are hereby transferred to AMT BV.

 

2.1.2.                           The Seller expressly confirms that the Purchasers shall not purchase or assume any other assets and liabilities than the Business Assets and Business Liabilities, and that all other assets and liabilities are excluded from the sale and purchase of the Business, including the Excluded Contracts.

 

2.1.3.                           The economic benefit and burden of the Business shall be for the risk and account of the Purchasers with effect as of the Effective Date, it being understood that the Business Assets and Business Liabilities, to the extent they relate to any period after the Effective Date, shall be for the risk and account of the Purchasers and that the Business Assets and Business Liabilities, to the extent they relate to any period before the Effective Date, shall be for the risk and account of the Seller.

 

2.1.4.                           The Seller covenants that it has the right to sell and transfer or assign (as the case may be) to the Purchasers the economic ownership of the Business on the terms and conditions set out in this Agreement.

 

2.1.5.                           In connection with the contribution set forth in Clause 2.1.1 above, the Seller hereby undertakes to transfer the legal title (juridische eigendom) to the Business to the Purchasers in accordance with Clause 3, whereby:

 

(A)                              the legal title to the Business Intellectual Property Rights will be transferred to AMT IP BV; and

 

(B)                              the legal title to the other Business Assets and Business Liabilities will be

 

2

 

transferred to AMT BV.

 

2.1.6.                           The respective parts of the Business shall be transferred to AMT IP BV and AMT BV by way of a contribution in kind (inbreng in natura) on the ordinary shares in the capital of the Purchasers held by the Seller, without the issuance of new shares. The value of the respective parts of the Business will be recorded as share premium (agiostorting) in the books of AMT IP BV and AMT BV.

 

2.2.                           Sale of the Seller Loans

 

The Seller and the Purchasers hereby agree to the transfer by the Seller to the Purchasers of the Seller Loans after signing of the BAA, but prior to the Completion Date unless such transfer has materially adverse consequences for the Seller or the Purchasers; such determination to be made by the Seller and the Purchasers jointly.

 

2.3.                           VAT

 

The Seller and the Purchasers are included in a fiscal unity for Dutch VAT purposes within the meaning of article 7 paragraph 4 Dutch VAT Act 1968 (Wet op de omzetbelasting 1968) and the Seller and the Purchasers expressly agree that the transfer of the economic ownership of the Business occurs within the fiscal unity for Dutch VAT and that therefore no VAT should become due as a result of such transfer.

 

3.                                     TRANSFER OF LEGAL TITLE

 

The transfer of the legal title to the Business by the Seller to the Purchasers, as meant in Clause 2.1.5, shall be implemented by means of the execution of a deed of assignment (the “Deed of Assignment”) and in connection therewith the Seller shall undertake all necessary actions, including but not limited to:

 

(A)                               informing the debtors of the Accounts Receivable in writing that the Accounts Receivable have been assigned to the Purchaser);

 

(B)                               requesting the counterparties to the Contracts in writing for their co-operation to the transfer of contract) to which the Seller is a party; and

 

(C)                               to the extent not already referred to in this Clause 3, the proper fulfilment of the applicable transfer requirements in respect of the Further Assets and Liabilities owned and/or held by the Seller.

 

The Parties shall take any and all further actions as needed to transfer the legal title to the Business from the Seller to the Purchasers.

 

4.                                     CONFIDENTIALITY AND ANNOUNCEMENTS

 

4.1.                           Confidentiality

 

4.1.1.                           Subject to Clause 4.1.2 and Clause 4.2, each Party shall treat as strictly confidential and not disclose or use any information relating to this Agreement or any ancillary matter and the negotiations leading up to this Agreement. The Seller shall not disclose or use any information in its possession relating to the Business following Completion and any information relating to the Purchaser.

 

3

 

4.1.2.                           The restrictions contained in Clause 4.1.1 shall not apply if and to the extent:

 

(A)                              disclosure is required by any Law or by a court;

 

(B)                              disclosure is required by any securities exchange or regulatory or governmental body;

 

(C)                              disclosure is necessary to enforce this Agreement in court proceedings.

 

(D)                              the other Party has given its written consent to disclosure;

 

(E)                               the information has come into the public domain through no fault of the relevant Party’s group;

 

(F)                                disclosure is necessary to obtain the advice of any professional adviser.

 

In the event of a disclosure of information pursuant to Clause 4.1.2 (A) or (B), the disclosing Party shall consult with the other Party as to the contents, form and timing of the disclosure to be made.

 

4.1.3.                           Each of the Parties shall ensure that each of its shareholder(s), subsidiaries, participations, managing directors or other employees are bound by and observe the restrictions in Clause 4.1.

 

4.2.                           Announcements

 

4.2.1.                           Subject to Clause 4.2.1, none of the Parties shall make any announcement before or after Completion with respect to this Agreement or any ancillary matter without the prior written consent of the other Party, that consent not to be unreasonably withheld or delayed.

 

4.2.2.                           Notwithstanding Clause 4.2.1, a Party may make an announcement with respect to this Agreement or any ancillary matter if required by any Law to which that Party is subject, provided that any such announcement shall be made by such Party only after consultation with the other Party.

 

5.                                     GENERAL PROVISIONS

 

5.1.                           Notices

 

All announcements or notices to the Parties will be done in writing and delivered to the relevant Party at its address specified in Schedule 8 of the BAA as long as a Party does not give notice to the other Parties of any other address.

 

5.2.                           Entire agreement

 

This Agreement constitutes the entire agreement between the Parties relating to the transfer of the economic ownership of the Business. This Agreement supersedes and terminates any preceding or concurrent oral or written agreements between the Parties and no Party shall have any right or remedy against any other Party arising out of or in connection with any such preceding or concurrent agreements unless stated otherwise in this Agreement.

 

4

 

5.3.                           Amendment

 

This Agreement may only be amended by mutual agreement in writing.

 

5.4.                           Assignment

 

None of the Parties may assign or procure the assumption of its rights and obligations under this Agreement, either in whole or in part, to any other person without the prior written consent of the other Party.

 

5.5.                           Partial invalidity

 

The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. Any such invalid or unenforceable provision shall be replaced or be deemed to be replaced by a provision that is considered to be valid and enforceable. The interpretation of the replacing provisions shall be as close as possible to the intent of the invalid or unenforceable provision.

 

5.6.                           Rescission after Completion

 

The Parties waive their right to rescind (ontbinden) this Agreement pursuant to Article 6:265 of the Dutch Civil Code after Completion.

 

5.7.                           Governing law

 

This Agreement is governed by the laws of the Netherlands, but excluding the Vienna Convention for the International Sale of Goods.

 

5.8.                           Jurisdiction

 

The competent court in Amsterdam, the Netherlands shall have exclusive jurisdiction to settle any dispute in connection with this Agreement without prejudice to the right of appeal and that of appeal to the Supreme Court.

 

5

 

THUS AGREED AND SIGNED IN AMSTERDAM ON 16 FEBRUARY 2012,

 

	
Amsterdam   Molecular Therapeutics (AMT) B.V.  
    	
 
    	
Amsterdam   Molecular Therapeutics (AMT) IP B.V.  
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: /s/Joern   Aldag, CEO
    	
 
    	
By: /s/Joern   Aldag, CEO
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/Piers   Morgan, CFO
    	
 
    	
By:
    	
/s/Piers   Morgan, CFO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Amsterdam   Molecular Therapeutics (AMT) Holding N.V.  
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: /s/Joern   Aldag, CEO
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/Piers   Morgan, CFO
    	
 
    	
 
    
					

 

6

 

SCHEDULE 1 (DEFINITIONS)

 

“Accounts Receivable” means all the accounts receivable of the Seller relating to the Business;

 

“Administration” means all the administration of the Group relating to the Business, whether in electronic or physical form, including but not limited to ownership titles of assets, bought and sold ledgers, purchase and sales day books and purchase and sales invoices, management information records and other accounting books and records of the Group including tax records relating to the Business;

 

“Agreement” means this Agreement for the sale and purchase of the economic ownership of certain assets and liabilities of the Seller to the Purchasers including the recitals and all Schedules, as amended in accordance with its terms;

 

“AMT BV” means Amsterdam Molecular Therapeutics (AMT) B.V.;

 

“AMT BV Seller Loan” means the intra Group loan agreement between the Seller (as lender) and AMT BV (as borrower) and all (existing and future) rights and obligations there under;

 

“AMT BV Shares” means all of the issued and outstanding shares in the share capital of AMT BV;

 

“AMT IP BV” means Amsterdam Molecular Therapeutics (AMT) IP B.V.;

 

“AMT IP BV Seller Loan” means the intra Group loan agreement between the Seller (as lender) and AMT IP BV (as borrower) and all (existing and future) rights and obligations thereunder;

 

“AMT IP BV Shares” means all of the issued and outstanding shares in the share capital of AMT IP BV;

 

“BAA” means the Business Acquisition Agreement entered on 16 February 2012 between the Seller, Kairos Therapeutics B.V. as the purchaser, Forbion Co-Investment II Coöperatief U.A., Coöperatieve AAC LS U.A. and FORBION Co-Investment COÖPERATIEF U.A. as the Investor, AMT BV and AMT IP BV as the Subsidiaries.

 

“Business” means all activities of the Seller, its operations and the Business Assets and the Business Liabilities;

 

“Business Assets” means all assets of the Sellers, including but not limited to its rights in respect of the Contracts, the Business Intellectual Property Rights, the Further Assets and Liabilities, the Business Goodwill and Know How, and any other asset related to the Business, and that have not expressly been excluded and excluding the Sale Shares and the Seller Loans;

 

“Business Goodwill and Know How” means any and all goodwill with respect to the Business, irrespective of whether such goodwill has been capitalised (geactiveerd), and all technical and other information in any form which is not in the public domain in respect of the Business (other than Business Intellectual Property Rights);

 

“Business Intellectual Property Rights” means the intellectual property rights of the Seller in relation to the Business, such as but not limited to (a) patents, trade marks, service marks, registered designs, trade, business and company names, internet domain names and e-mail addresses, unregistered trade marks and service marks, copyrights, database rights, know how, 

 

7

 

rights in designs and inventions and applications and rights to apply for any of those rights; (b) the rights to sue for past infringements of any of the foregoing rights, including the intellectual property rights listed in Schedule 2;

 

“Business Liabilities” means all bona fide liabilities of the Seller in respect of the Business that have not expressly been excluded, and all other liabilities expressly assumed by the Purchasers under this Agreement, excluding the Loan Notes and the Convertible Loan Note Agreement;

 

“Business Day” means a day, other than a Saturday or a Sunday, on which the banks in Amsterdam are open for normal business;

 

“Completion Date” means the date on which the completion of the BAA shall occur;

 

“Contracts” means all contracts entered into by the Seller relating to the Business and all (existing and future) rights and obligations thereunder, including those specified in Schedule 2, but excluding the Excluded Contracts;

 

“Convertible Loan Note Agreement” means the agreement constituting the issuance of loan notes dated 22 December 2009 and made by the Seller and Coöperatieve AAC LS U.A. and Forbion Co-Investment Coöperatief U.A. and all existing and future rights and obligations of the Seller there under;

 

“Excluded Contracts” means this Agreement, the BAA, the listing agreement between the Seller and Euronext Amsterdam, the contract with the ENL agent and the payment agent, the liquidity provider agreement between the Seller and Kempen & Co N.V., the D&O Insurance policy of the Seller and any outstanding obligations under any stock option plan or other employee benefit plan of the Seller;

 

“Further Assets and Liabilities” means the Accounts Receivable, Intra-Group Trading Items and Contracts and any further assets and liabilities of the Group as further specified in Schedule 2;

 

“Group” means the Seller and the Purchasers collectively;

 

“Intra-Group Trading Items” means at any time, and from time to time, all amounts owed, outstanding or accrued in the ordinary course of trading as between the Seller and the Purchasers in respect of intra group trading activity between them;

 

“Law” means any law, regulation, directive, covenant, guideline, standard, circular or general policy rule of any governmental or regulatory body in any jurisdiction;

 

“Loan Note 1” means the €700,000 5% convertible loan note due 2014 of the Seller dated 23 December 2009 and issued to and held by Coöperatieve AAC LS U.A. which is constituted by the Convertible Loan Note Agreement, and all the existing and future rights and obligations of the Seller there under;

 

“Loan Note 2” means the €4,300,000 5% convertible loan note due 2014 of the Seller dated 23 December 2009 and issued to and held by Forbion Co-Investment Coöperatief U.A. which is constituted by the Convertible Loan Note Agreement, and all the existing and future rights and obligations of the Seller there under;

 

“Loan Notes” means the Loan Note 1 and the Loan Note 2 collectively;

 

“Purchaser” has the meaning given in the opening of this Agreement;

 

8

 

“Reorganisation” has the meaning given in recital (E) of the BAA;

 

“Sale Shares” means the AMT IP BV Shares and the AMT BV Shares;

 

“Seller” has the meaning given in the opening of this Agreement;

 

“Seller Loans” means the AMT BV Seller Loan and the AMT IP BV Seller Loan collectively;

 

“Signing Date” means 16 February 2012, being the date on which the BAA is signed and dated;

 

“VAT” means value added taxation within the meaning of the VAT Act 1968 (Wet op de omzetbelasting 1968).

 

9

 

SCHEDULE 2

 

(BUSINESS INTELLECTUAL PROPERTY RIGHTS &

 

FURTHER ASSETS AND LIABILITIES)

 

LIST OF TRADEMARKS

 

	
 
    	
 
    	
Catchword
    	
 
    	
Type
    	
 
    	
Country
    	
 
    	
Classes
    	
 
    	
Appl.No.
    	
 
    	
Appl.date
    	
 
    	
Reg.No.
    	
 
    	
Reg.date
    	
 
    	
Ren.date
    	
 
    	
Applicant
    	
 
    	
Status
    	
 
    	
Case No.
    	
 
    	
Watch
    
	
1. 
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
209906
    	
 
    	
24-03-08.
    	
 
    	
209906
    	
 
    	
07-02-10.
    	
 
    	
24-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005IL00
    	
 
    	
No
    
	
2. 
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
10692009
    	
 
    	
22-04-09.
    	
 
    	
3772009
    	
 
    	
02-06-09.
    	
 
    	
02-06-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005IS00
    	
 
    	
No
    
	
3. 
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
100494
    	
 
    	
23-04-08.
    	
 
    	
100494
    	
 
    	
23-04-08.
    	
 
    	
23-04-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005JO00
    	
 
    	
No
    

 

 

	
4.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200905089
    	
 
    	
21-04-09.
    	
 
    	
251774
    	
 
    	
14-07-09.
    	
 
    	
14-07-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005NO00
    	
 
    	
No
    
	
5.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
200925333
    	
 
    	
18-05-09.
    	
 
    	
200925333
    	
 
    	
04-05-10.
    	
 
    	
18-05-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005TR00
    	
 
    	
No
    
	
6.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
113972
    	
 
    	
03-06-08.
    	
 
    	
150481
    	
 
    	
09-12-11.
    	
 
    	
03-06-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004AE00
    	
 
    	
No
    
	
7.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
64727
    	
 
    	
18-03-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004BH00
    	
 
    	
No
    
	
8.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
IR
    	
 
    	
05
    	
 
    	
86122678
    	
 
    	
18-03-08.
    	
 
    	
157479
    	
 
    	
14-09-08.
    	
 
    	
18-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004IR00
    	
 
    	
No
    
	
9.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
2449
    	
 
    	
08-04-08.
    	
 
    	
116062
    	
 
    	
24-04-08.
    	
 
    	
24-04-23.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004LB00
    	
 
    	
No
    
	
10.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
17093
    	
 
    	
05-02-09.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004LY00
    	
 
    	
No
    
	
11.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
118083
    	
 
    	
19-06-08.
    	
 
    	
118083
    	
 
    	
17-11-08.
    	
 
    	
19-06-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004MA00
    	
 
    	
No
    

 

2

 

	
12.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
49398
    	
 
    	
19-03-08.
    	
 
    	
49398
    	
 
    	
11-08-09.
    	
 
    	
19-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004OM00
    	
 
    	
No
    
	
13.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
50165
    	
 
    	
03-04-08.
    	
 
    	
50165
    	
 
    	
20-03-11.
    	
 
    	
03-04-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004QA00
    	
 
    	
No
    
	
14.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707490
    	
 
    	
14-03-08.
    	
 
    	
381651
    	
 
    	
16-06-09.
    	
 
    	
14-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004RU00
    	
 
    	
No
    
	
15.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
3814
    	
 
    	
22-04-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004SY00
    	
 
    	
No
    
	
16.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE080755
    	
 
    	
19-03-08.
    	
 
    	
EE080755
    	
 
    	
26-01-10.
    	
 
    	
19-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004TN00
    	
 
    	
No
    
	
17.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
05
    	
 
    	
77/421590
    	
 
    	
13-03-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004US00
    	
 
    	
No
    
	
18.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200805836
    	
 
    	
14-03-08.
    	
 
    	
200805836
    	
 
    	
14-03-08.
    	
 
    	
14-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004ZA00
    	
 
    	
No
    
	
19.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
101941
    	
 
    	
31-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001AE00
    	
 
    	
Yes
    

 

3

 

	
20.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
AU
    	
 
    	
05
    	
 
    	
1176048
    	
 
    	
14-05-07.
    	
 
    	
1176048
    	
 
    	
12-12-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001AU00
    	
 
    	
Yes
    
	
21.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
62689
    	
 
    	
07-01-08.
    	
 
    	
62689
    	
 
    	
07-01-08.
    	
 
    	
07-01-18.
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001BH00
    	
 
    	
Yes
    
	
22.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
DZ
    	
 
    	
05
    	
 
    	
72791
    	
 
    	
24-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001DZ00
    	
 
    	
Yes
    
	
23.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
EG
    	
 
    	
05
    	
 
    	
208229
    	
 
    	
22-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001EG00
    	
 
    	
Yes
    
	
24.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
204800
    	
 
    	
21-10-07.
    	
 
    	
204800
    	
 
    	
11-08-09.
    	
 
    	
21-10-17.
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001IL00
    	
 
    	
Yes
    
	
25.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
14642007
    	
 
    	
14-05-07.
    	
 
    	
8122007
    	
 
    	
04-07-07.
    	
 
    	
04-07-17.
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001IS00
    	
 
    	
Yes
    
	
26.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
99133
    	
 
    	
24-10-07.
    	
 
    	
99133
    	
 
    	
01-05-07.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001JO00
    	
 
    	
Yes
    
	
27.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
6612
    	
 
    	
23-10-07.
    	
 
    	
113370
    	
 
    	
25-10-07.
    	
 
    	
25-10-22.
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001LB00
    	
 
    	
Yes
    
	
28.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
16593
    	
 
    	
22-12-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular Therapeutics
   (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001LY00
    	
 
    	
Yes
    

 

4

 

	
29.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
113550
    	
 
    	
23-10-07.
    	
 
    	
113550
    	
 
    	
23-10-07.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001MA00
    	
 
    	
Yes
    
	
30.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200705606
    	
 
    	
15-05-07.
    	
 
    	
241553
    	
 
    	
19-10-07.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001NO00
    	
 
    	
Yes
    
	
31.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
NZ
    	
 
    	
05
    	
 
    	
768310
    	
 
    	
14-05-07.
    	
 
    	
768310
    	
 
    	
15-11-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001NZ00
    	
 
    	
Yes
    
	
32.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
47462
    	
 
    	
22-10-07.
    	
 
    	
47462
    	
 
    	
24-08-08.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001OM00
    	
 
    	
Yes
    
	
33.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
47253
    	
 
    	
31-10-07.
    	
 
    	
47253
    	
 
    	
31-12-09.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001QA00
    	
 
    	
Yes
    
	
34.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707340
    	
 
    	
13-03-08.
    	
 
    	
377215
    	
 
    	
20-04-09.
    	
 
    	
13-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001RU00
    	
 
    	
Yes
    
	
35.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
SA
    	
 
    	
05
    	
 
    	
125692
    	
 
    	
12-01-08.
    	
 
    	
1156/45
    	
 
    	
25-04-10.
    	
 
    	
12-09-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001SA00
    	
 
    	
Yes
    
	
36.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
4268
    	
 
    	
28-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001SY00
    	
 
    	
Yes
    
	
37.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE072667
    	
 
    	
24-10-07.
    	
 
    	
EE072667
    	
 
    	
19-05-09.
    	
 
    	
24-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001TN00
    	
 
    	
Yes
    

 

5

 

	
38.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
2007026778
    	
 
    	
17-05-07.
    	
 
    	
200726778
    	
 
    	
17-05-07.
    	
 
    	
17-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001TR00
    	
 
    	
Yes
    
	
39.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200723919
    	
 
    	
19-10-07.
    	
 
    	
2007/23919
    	
 
    	
19-10-07.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001ZA00
    	
 
    	
Yes
    
	
40.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
101942
    	
 
    	
31-10-07.
    	
 
    	
100927
    	
 
    	
24-03-10.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002AE00
    	
 
    	
Yes
    
	
41.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
AU
    	
 
    	
05
    	
 
    	
1176051
    	
 
    	
14-05-07.
    	
 
    	
1176051
    	
 
    	
12-12-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002AU00
    	
 
    	
Yes
    
	
42.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
62690
    	
 
    	
07-01-08.
    	
 
    	
62690
    	
 
    	
07-01-08.
    	
 
    	
07-01-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002BH00
    	
 
    	
Yes
    
	
43.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
DZ
    	
 
    	
05
    	
 
    	
72793
    	
 
    	
24-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002DZ00
    	
 
    	
Yes
    
	
44.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
EG
    	
 
    	
05
    	
 
    	
208203
    	
 
    	
22-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002EG00
    	
 
    	
Yes
    
	
45.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
204915
    	
 
    	
23-10-07.
    	
 
    	
204915
    	
 
    	
11-08-09.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002IL00
    	
 
    	
Yes
    
	
46.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
IR
    	
 
    	
05
    	
 
    	
86091403
    	
 
    	
08-12-07.
    	
 
    	
157475
    	
 
    	
14-09-08.
    	
 
    	
08-12-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002IR00
    	
 
    	
Yes
    

 

6

 

	
47.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
14632007
    	
 
    	
14-05-07.
    	
 
    	
8112007
    	
 
    	
04-07-07.
    	
 
    	
04-07-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002IS00
    	
 
    	
Yes
    
	
48.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
99366
    	
 
    	
24-10-07.
    	
 
    	
99366
    	
 
    	
14-01-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002JO00
    	
 
    	
Yes
    
	
49.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
6622
    	
 
    	
23-10-07.
    	
 
    	
113434
    	
 
    	
30-10-07.
    	
 
    	
30-10-22.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002LB00
    	
 
    	
Yes
    
	
50.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
16595
    	
 
    	
22-12-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002LY00
    	
 
    	
Yes
    
	
51.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
113551
    	
 
    	
23-10-07.
    	
 
    	
113551
    	
 
    	
23-10-07.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002MA00
    	
 
    	
Yes
    
	
52.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200705604
    	
 
    	
15-05-07.
    	
 
    	
241558
    	
 
    	
22-10-07.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002NO00
    	
 
    	
Yes
    
	
53.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
NZ
    	
 
    	
05
    	
 
    	
768309
    	
 
    	
14-05-07.
    	
 
    	
768309
    	
 
    	
12-02-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002NZ00
    	
 
    	
Yes
    
	
54.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
47461
    	
 
    	
22-10-07.
    	
 
    	
47461
    	
 
    	
30-05-09.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002OM00
    	
 
    	
Yes
    
	
55.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
47255
    	
 
    	
31-10-07.
    	
 
    	
47255
    	
 
    	
31-12-09.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002QA00
    	
 
    	
Yes
    

 

7

 

	
56.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707342
    	
 
    	
13-03-08.
    	
 
    	
381400
    	
 
    	
10-06-09.
    	
 
    	
13-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002RU00
    	
 
    	
Yes
    
	
57.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
SA
    	
 
    	
05
    	
 
    	
125693
    	
 
    	
12-01-08.
    	
 
    	
1171/48
    	
 
    	
19-06-10.
    	
 
    	
12-09-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002SA00
    	
 
    	
Yes
    
	
58.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
4269
    	
 
    	
28-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002SY00
    	
 
    	
Yes
    
	
59.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE072666
    	
 
    	
24-10-07.
    	
 
    	
EE072666
    	
 
    	
19-05-09.
    	
 
    	
24-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002TN00
    	
 
    	
Yes
    
	
60.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
2007026779
    	
 
    	
17-05-07.
    	
 
    	
200726779
    	
 
    	
17-05-07.
    	
 
    	
17-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002TR00
    	
 
    	
Yes
    
	
61.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200723918
    	
 
    	
19-10-07.
    	
 
    	
2007/23918
    	
 
    	
19-10-07.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002ZA00
    	
 
    	
Yes
    
	
62.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
101943
    	
 
    	
31-10-07.
    	
 
    	
100909
    	
 
    	
24-03-10.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003AE00
    	
 
    	
Yes
    
	
63.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
AU
    	
 
    	
05
    	
 
    	
1176049
    	
 
    	
14-05-07.
    	
 
    	
1176049
    	
 
    	
12-12-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003AU00
    	
 
    	
Yes
    
	
64.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
62691
    	
 
    	
07-01-08.
    	
 
    	
62691
    	
 
    	
07-01-08.
    	
 
    	
07-01-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003BH00
    	
 
    	
Yes
    

 

8

 

	
65.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
DZ
    	
 
    	
05
    	
 
    	
72792
    	
 
    	
24-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003DZ00
    	
 
    	
Yes
    
	
66.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
EG
    	
 
    	
05
    	
 
    	
208231
    	
 
    	
22-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003EG00
    	
 
    	
Yes
    
	
67.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
204799
    	
 
    	
21-10-07.
    	
 
    	
204799
    	
 
    	
11-04-09.
    	
 
    	
21-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003IL00
    	
 
    	
Yes
    
	
68.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
IR
    	
 
    	
05
    	
 
    	
86091401
    	
 
    	
08-12-07.
    	
 
    	
158201
    	
 
    	
14-09-08.
    	
 
    	
08-12-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003IR00
    	
 
    	
Yes
    
	
69.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
14652007
    	
 
    	
14-05-07.
    	
 
    	
8132007
    	
 
    	
04-07-07.
    	
 
    	
04-07-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003IS00
    	
 
    	
Yes
    
	
70.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
99208
    	
 
    	
24-10-07.
    	
 
    	
99208
    	
 
    	
03-03-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003JO00
    	
 
    	
Yes
    
	
71.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
6623
    	
 
    	
23-10-07.
    	
 
    	
113437
    	
 
    	
30-10-07.
    	
 
    	
30-10-22.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003LB00
    	
 
    	
Yes
    
	
72.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
16594
    	
 
    	
22-12-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003LY00
    	
 
    	
Yes
    
	
73.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
113552
    	
 
    	
23-10-07.
    	
 
    	
113552
    	
 
    	
23-10-07.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003MA00
    	
 
    	
Yes
    

 

9

 

	
74.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200705605
    	
 
    	
15-05-07.
    	
 
    	
241517
    	
 
    	
18-10-07.
    	
 
    	
18-10-17.
    	
 
    	
Amsterdam Molecular Therapeutics   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003NO00
    	
 
    	
Yes
    
	
75.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
NZ
    	
 
    	
05
    	
 
    	
768311
    	
 
    	
14-05-07.
    	
 
    	
768311
    	
 
    	
15-11-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003NZ00
    	
 
    	
Yes
    
	
76.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
47463
    	
 
    	
22-10-07.
    	
 
    	
47463
    	
 
    	
30-05-09.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003OM00
    	
 
    	
Yes
    
	
77.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
47254
    	
 
    	
31-10-07.
    	
 
    	
47254
    	
 
    	
31-12-09.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003QA00
    	
 
    	
Yes
    
	
78.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707341
    	
 
    	
13-03-08.
    	
 
    	
394999
    	
 
    	
01-12-09.
    	
 
    	
13-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003RU00
    	
 
    	
Yes
    
	
79.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
SA
    	
 
    	
05
    	
 
    	
125694
    	
 
    	
12-01-08.
    	
 
    	
1171/49
    	
 
    	
19-06-10.
    	
 
    	
12-09-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003SA00
    	
 
    	
Yes
    
	
80.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
4267
    	
 
    	
28-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003SY00
    	
 
    	
Yes
    
	
81.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE072668
    	
 
    	
24-10-07.
    	
 
    	
EE072668
    	
 
    	
19-05-09.
    	
 
    	
24-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003TN00
    	
 
    	
Yes
    
	
82.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
2007026780
    	
 
    	
17-05-07.
    	
 
    	
200726780
    	
 
    	
07-04-08.
    	
 
    	
17-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003TR00
    	
 
    	
Yes
    

 

10

 

	
83.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
05
    	
 
    	
77/179359
    	
 
    	
11-05-07.
    	
 
    	
3855311
    	
 
    	
05-10-10.
    	
 
    	
05-10-20.
    	
 
    	
 
    	
 
    	
Registered
    	
 
    	
T56003US00
    	
 
    	
Yes
    
	
84.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200723917
    	
 
    	
19-10-07.
    	
 
    	
200723917
    	
 
    	
14-07-10.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003ZA00
    	
 
    	
Yes
    

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]